- OPCML tumor suppressor therapy effectively replaces a crucial protein that blocks cancer in almost half of all human cancers
- OPCML therapy acts at the cell surface, without the need to restore the tumor suppressor inside every cancer cell
- Restoration of OPCML reverses the cancer state as well as activating anti-tumor immunity
- It therefore functions in cancer like insulin for diabetes
- OPCML tumor suppressor therapy synergizes with chemotherapy, RTK inhibitors and immunotherapy
- Predictive biomarkers can select patients likely to benefit
- In addition to tumor suppressor protein replacement therapy, gene replacement therapy can be considered
- Initial lines of sight include brain, colorectal and ovarian tumors
